PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPemetrexed
Alimta(pemetrexed)
Alimta, Armisarte, Axtle, Ciambra, Pemetrexed, Pemfexy (pemetrexed) is a small molecule pharmaceutical. Pemetrexed was first approved as Alimta on 2004-02-04. It is used to treat mesothelial neoplasms and non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat mesothelioma and non-small-cell lung carcinoma. The pharmaceutical is active against dihydrofolate reductase. In addition, it is known to target proton-coupled folate transporter, thymidylate synthase, and trifunctional purine biosynthetic protein adenosine-3.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Alimta, Pemetrexed, Pemetrexed ditromethamine, Pemfexy (discontinued: Pemetrexed, Pemetrexed ditromethamine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pemetrexed disodium
Tradename
Company
Number
Date
Products
PEMETREXED DISODIUMAccord HealthcareN-214408 RX2022-07-19
4 products, RLD, RS
PEMETREXED DISODIUMHospiraN-214218 RX2022-06-22
3 products, RLD, RS
ALIMTAEli LillyN-021462 RX2004-02-04
2 products, RLD, RS
PEMETREXED DISODIUMSandozN-214657 RX2022-05-26
3 products, RLD, RS
PEMETREXEDShilpa MedicareN-215179 RX2023-05-22
3 products, RLD, RS
Pemetrexed
Tradename
Company
Number
Date
Products
PEMETREXEDAllerganN-208419 RX2020-08-21
3 products, RLD, RS
PEMFEXYEagle PharmaceuticalsN-209472 RX2020-02-08
1 products, RLD, RS
Pemetrexed ditromethamine
Tradename
Company
Number
Date
Products
PEMETREXED DITROMETHAMINEHospiraN-208746 RX2022-06-10
2 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
alimtaNew Drug Application2023-05-19
axtleNew Drug Application2024-12-27
pemetrexedNew Drug Application2024-11-28
pemetrexed dipotassiumNew Drug Application2025-02-05
pemetrexed disodiumANDA2022-11-15
pemfexyNew Drug Application2023-05-15
pemrydi rtuNew Drug Application2024-11-11
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
non-small-cell lung carcinoma—D002289—
mesothelial neoplasms—D018301—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Pemetrexed, Pemfexy, Eagle Pharms
96049902035-10-28DP
Pemetrexed Disodium, Pemetrexed, Shilpa
111478172035-03-26DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01B: Antimetabolites
— L01BA: Folic acid analogs, antimetabolites
— L01BA04: Pemetrexed
HCPCS
Code
Description
J9304
Injection, pemetrexed (pemfexy), 10 mg
J9305
Injection, pemetrexed, not otherwise specified, 10 mg
Clinical
Clinical Trials
1330 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289——1685092381953899
Lung neoplasmsD008175—C34.901254121781244707
NeoplasmsD009369—C8088421323126
MesotheliomaD008654—C4536631247101
Malignant mesotheliomaD000086002——3362123695
AdenocarcinomaD000230——82995754
Adenocarcinoma of lungD000077192——62955749
LymphomaD008223—C85.956—1—11
ThymomaD013945——11—1—3
Renal insufficiencyD051437—N19———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.0204014—168
Neoplasm metastasisD009362EFO_0009708—19334—453
Brain neoplasmsD001932EFO_0003833C712193——24
Small cell lung carcinomaD055752——6143——22
Head and neck neoplasmsD006258——8142——21
Ovarian neoplasmsD010051EFO_0003893C569111——18
Urologic neoplasmsD014571—C64-C68691——13
RecurrenceD012008——2101—113
Transitional cell carcinomaD002295——2102——12
Uterine cervical neoplasmsD002583——345——12
Show 23 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179——1617———27
Breast neoplasmsD001943EFO_0003869C501119———26
Meningeal carcinomatosisD055756EFO_1001012—912——317
MelanomaD008545——97———11
Renal cell carcinomaD002292EFO_0000376—75———9
SarcomaD012509——36———9
ImmunotherapyD007167———5——27
Peritoneal neoplasmsD010534——35———7
Triple negative breast neoplasmsD064726——44———6
Squamous cell carcinoma of head and neckD000077195——43———6
Show 77 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Primary myelofibrosisD055728—D47.42————2
Uveal neoplasmsD014604EFO_1001230—2————2
Uveal melanomaD000098943——2————2
Skin neoplasmsD012878EFO_0004198C441————1
Cutaneous malignant melanomaD000096142——1————1
Non-hodgkin lymphomaD008228—C85.91————1
Hodgkin diseaseD006689—C811————1
PharmacokineticsD010599——1————1
Medical sociologyD012962——1————1
LeukemiaD007938—C951————1
Show 13 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PulpitisD011671EFO_1001139K04.0————44
DiseaseD004194EFO_0000408R69————22
NeutropeniaD009503—D70————22
MethylationD008745——————11
Multiple primary neoplasmsD009378——————11
LasersD007834——————11
PeriodontitisD010518EFO_0000649K05.3————11
Periapical periodontitisD010485EFO_1001391K04.5————11
Wound healingD014945GO_0042060—————11
Nonvital toothD019553——————11
Show 14 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePemetrexed
INNpemetrexed
Description
Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC)..
Classification
Small molecule
Drug classantineoplastic thymidylate synthetase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1
Identifiers
PDB—
CAS-ID137281-23-3
RxCUI—
ChEMBL IDCHEMBL225072
ChEBI ID63616
PubChem CID446556
DrugBankDB00642
UNII ID04Q9AIZ7NO (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Pemfexy – Eagle Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Alimta – Eli Lilly
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 23,796 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
30,897 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use